Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial

By sjmartinez • July 1, 2025

Ledermann JA, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Lebreton C, Konecny GE, McNeish IA, Scott CL, Maloney L, Goble S, Lin KK, Coleman RL. Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial. Eur J Cancer. 2025 Jun 17;225:115584. doi: 10.1016/j.ejca.2025.115584. Epub ahead of print. PMID: 40580808.

Tags: ADP-ribose, BRCA, Hematology/Oncology, Homologous recombination deficient, Long-term follow-up, overall survival, PFS2, Poly polymerase inhibitor, Progression-free interval, Publications, Recurrent ovarian cancer

Intermediate endpoints as surrogates for long term outcomes in breast cancer adjuvant chemotherapy trials

Blasco A, López-Tarruella S, Urruticoechea A, Carrasco E, Spera G, Martín M, Bermejo B, Chap L, Ruiz-Borrego M, Crown J, García-Saenz JA, Chan A, Guerrero-Zotano[...]

Phase II study of the efficacy and safety of palbociclib in patients with recurrent ovarian cancer

Konecny GE, Davidson TM, Lebreton CL, Marsh LA, Chetram DK, Atkinson HJ, Larson MC, Oberg AL, Abdelaal N, Silverstein J, Jatoi A, Washburn A, Burton[...]

Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma

Nassar AH, Kim C, Adeyelu T, Bou Farhat E, Abushukair H, Rakaee M, Matteson K, Lau SF, Takabe Y, Ocejo A, Ardeshir-Larijani F, Leal T,[...]